605116 奥锐特
已收盘 12-19 15:00:00
资讯
新帖
简况
奥锐特（605116）披露通过药品GMP符合性检查，12月18日股价上涨0.59%
证券之星 · 12-18 22:36
奥锐特（605116）披露通过药品GMP符合性检查，12月18日股价上涨0.59%
奥锐特(605116.SH)通过药品GMP符合性检查
智通财经 · 12-18 16:52
奥锐特(605116.SH)通过药品GMP符合性检查
奥锐特（605116）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨1.06%
证券之星 · 12-01
奥锐特（605116）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨1.06%
奥锐特：11月24日高管赵珍平减持股份合计10000股
证券之星 · 11-25
奥锐特：11月24日高管赵珍平减持股份合计10000股
奥锐特(605116.SH)子公司获雌二醇片/雌二醇地屈孕酮片复合包装注册批件
智通财经 · 11-25
奥锐特(605116.SH)子公司获雌二醇片/雌二醇地屈孕酮片复合包装注册批件
每周股票复盘：奥锐特（605116）回购股份2,224,738股用于转债转换
证券之星 · 11-23
每周股票复盘：奥锐特（605116）回购股份2,224,738股用于转债转换
每周股票复盘：奥锐特（605116）高管赵珍平两日减持合计2.57万股
证券之星 · 11-16
每周股票复盘：奥锐特（605116）高管赵珍平两日减持合计2.57万股
奥锐特（605116）披露召开2025年第三季度业绩说明会公告，11月14日股价上涨0.77%
证券之星 · 11-14
奥锐特（605116）披露召开2025年第三季度业绩说明会公告，11月14日股价上涨0.77%
奥锐特：11月12日高管赵珍平减持股份合计2万股
证券之星 · 11-13
奥锐特：11月12日高管赵珍平减持股份合计2万股
奥锐特：11月11日高管赵珍平减持股份合计5700股
证券之星 · 11-12
奥锐特：11月11日高管赵珍平减持股份合计5700股
每周股票复盘：奥锐特（605116）高管减持1.0万股且回购进展更新
证券之星 · 11-09
每周股票复盘：奥锐特（605116）高管减持1.0万股且回购进展更新
奥锐特（605116）206.6万股限售股将于11月7日解禁，占总股本0.51%
证券之星 · 11-07
奥锐特（605116）206.6万股限售股将于11月7日解禁，占总股本0.51%
奥锐特（605116）披露股东减持股份计划公告，11月04日股价下跌2.41%
证券之星 · 11-04
奥锐特（605116）披露股东减持股份计划公告，11月04日股价下跌2.41%
奥锐特(605116.SH)：天台铂恩拟减持不超0.25%股份
智通财经 · 11-04
奥锐特(605116.SH)：天台铂恩拟减持不超0.25%股份
股市必读：奥锐特(605116)股东户数1.15万户，较上期减少2.17%
中金财经 · 11-03
股市必读：奥锐特(605116)股东户数1.15万户，较上期减少2.17%
每周股票复盘：奥锐特（605116）Q3净利增24.62%
证券之星 · 11-02
每周股票复盘：奥锐特（605116）Q3净利增24.62%
奥锐特（605116）披露2022年限制性股票激励计划第三个解除限售期解除限售条件成就暨上市流通公告，10月31日股价上涨2.06%
中金财经 · 10-31
奥锐特（605116）披露2022年限制性股票激励计划第三个解除限售期解除限售条件成就暨上市流通公告，10月31日股价上涨2.06%
奥锐特(605116)9月30日股东户数1.15万户，较上期减少2.17%
证券之星 · 10-31
奥锐特(605116)9月30日股东户数1.15万户，较上期减少2.17%
图解奥锐特三季报：第三季度单季净利润同比增长24.62%
证券之星 · 10-30
图解奥锐特三季报：第三季度单季净利润同比增长24.62%
每周股票复盘：奥锐特（605116）可转债累计转股313股
证券之星 · 10-12
每周股票复盘：奥锐特（605116）可转债累计转股313股
暂无数据
公司概况
公司名称：
奥锐特药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-09-21
主营业务：
奥锐特药业股份有限公司的主营业务是特色复杂原料药、医药中间体和制剂的研发、生产和销售。公司的主要产品是呼吸系统、心血管、抗感染、神经系统、抗肿瘤和女性健康类产品。
发行价格：
8.37
{"stockData":{"symbol":"605116","market":"SH","secType":"STK","nameCN":"奥锐特","latestPrice":22.25,"timestamp":1766127601000,"preClose":22.08,"halted":0,"volume":1324300,"delay":0,"changeRate":0.0077,"floatShares":405999999,"shares":405999999,"eps":1.0452,"marketStatus":"已收盘","change":0.17,"latestTime":"12-19 15:00:00","open":22.11,"high":22.3,"low":22,"amount":29387400,"amplitude":0.0136,"askPrice":22.25,"askSize":18,"bidPrice":22.24,"bidSize":42,"shortable":0,"etf":0,"ttmEps":1.0452,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":22.08,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":24.29,"lowLimit":19.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":406195234,"isCdr":false,"pbRate":3.58,"roa":"--","peRate":21.287792,"roe":"14.37%","epsLYR":0.89,"committee":-0.32746,"marketValue":9038000000,"turnoverRate":0.0033,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-22。","floatMarketCap":9038000000},"requestUrl":"/m/hq/s/605116/tweets","defaultTab":"tweets","newsList":[{"id":"2592902615","title":"奥锐特（605116）披露通过药品GMP符合性检查，12月18日股价上涨0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902615","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902615?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:36","pubTimestamp":1766068583,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，奥锐特报收于22.08元，较前一交易日上涨0.59%，最新总市值为89.69亿元。近日，奥锐特药业股份有限公司发布关于通过药品GMP符合性检查的公告。公告称，公司收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》，公司位于浙江省天台县八都工业园区的806、863车间A3生产线和802车间BETB生产线通过药品GMP符合性检查，检查时间为2025年11月12日至11月14日，结论为符合《药品生产质量管理规范》及相关法规要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800039164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2592197644","title":"奥锐特(605116.SH)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592197644?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:52","pubTimestamp":1766047930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》(浙2025第0267号、浙2025第0268号)，检查范围及相关车间、生产线：1.原料药(糠酸莫米松)：806、863车间，A3生产线;2.原料药(倍他米松)：802车间，BETB生产线。公司本次通过药品GMP符合性检查，表明公司相关生产线符合GMP要求，将有利于公司继续保持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。本次获得药品GMP符合性检查结果不会对公司业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2588775073","title":"奥锐特（605116）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588775073?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:35","pubTimestamp":1764599711,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，奥锐特报收于22.89元，较前一交易日上涨1.06%，最新总市值为92.98亿元。近日，奥锐特药业股份有限公司发布关于以集中竞价交易方式回购公司股份的进展公告。公告显示，截至2025年11月30日，公司通过集中竞价交易方式累计回购股份2,350,238股，占公司总股本的0.58%，已支付资金总额48,999,398.68元，回购价格区间为18.83元/股至22.59元/股。本次回购股份用于转换公司可转债，回购期限为2025年1月21日至2026年1月20日，资金总额预计6,000万元至12,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2586420535","title":"奥锐特：11月24日高管赵珍平减持股份合计10000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420535","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586420535?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:02","pubTimestamp":1764072162,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月25日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2025年11月24日公司高级管理人员赵珍平共减持公司股份1.0万股，占公司总股本为0.0025%。变动期间公司股价上涨0.0%，11月24日当日收盘报21.99元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500034265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2586473994","title":"奥锐特(605116.SH)子公司获雌二醇片/雌二醇地屈孕酮片复合包装注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473994","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473994?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:36","pubTimestamp":1764056205,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司全资子公司扬州奥锐特药业有限公司(简称“扬州奥锐特”)收到国家药品监督管理局核准签发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品注册证书》。该药品用于治疗自然或术后绝经所致的围绝经期综合征。本次扬州奥锐特的雌二醇片/雌二醇地屈孕酮片复合包装(注册商标“奥舒桐”)按照化学药品新注册分类方法获得药品注册批件，有利于提升公司在该药品领域的市场竞争力，同时新批准产品在国内上市销售，有望对公司经营业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥锐特(605116.SH)子公司获雌二醇片/雌二醇地屈孕酮片复合包装注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2585105544","title":"每周股票复盘：奥锐特（605116）回购股份2,224,738股用于转债转换","url":"https://stock-news.laohu8.com/highlight/detail?id=2585105544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585105544?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:27","pubTimestamp":1763839631,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，奥锐特报收于21.99元，较上周的23.52元下跌6.51%。本周，奥锐特11月17日盘中最高价报23.9元。本周关注点公司公告汇总：奥锐特药业股份有限公司累计回购股份2,224,738股，占总股本0.55%。公司公告汇总奥锐特药业股份有限公司自2025年11月1日至11月21日，通过集中竞价交易方式累计回购股份2,224,738股，占公司总股本的0.55%，回购价格区间为18.83元/股至22.59元/股，支付资金总额46,231,070.68元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2583544136","title":"每周股票复盘：奥锐特（605116）高管赵珍平两日减持合计2.57万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583544136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583544136?lang=zh_cn&edition=full","pubTime":"2025-11-16 05:05","pubTimestamp":1763240715,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，奥锐特报收于23.52元，较上周的22.84元上涨2.98%。本周，奥锐特11月14日盘中最高价报23.8元。本周关注点股本股东变化：高管赵珍平两日合计减持2.57万股，占总股本0.0063%。股本股东变化高管增减持2025年11月12日，公司高级管理人员赵珍平减持2.0万股，占公司总股本0.0049%，当日收盘价23.34元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2583850769","title":"奥锐特（605116）披露召开2025年第三季度业绩说明会公告，11月14日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850769","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583850769?lang=zh_cn&edition=full","pubTime":"2025-11-14 23:03","pubTimestamp":1763132600,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，奥锐特报收于23.52元，较前一交易日上涨0.77%，最新总市值为95.54亿元。公司近日发布公告称，奥锐特药业股份有限公司将于2025年11月24日13:00-14:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果和财务状况。投资者可于11月17日至11月21日16:00前通过上证路演中心网站或公司邮箱ir@aurisco.com提交问题，公司在说明会上将对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2583556231","title":"奥锐特：11月12日高管赵珍平减持股份合计2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583556231?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:02","pubTimestamp":1763035332,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月13日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2025年11月12日公司高级管理人员赵珍平共减持公司股份2.0万股，占公司总股本为0.0049%。变动期间公司股价上涨2.14%，11月12日当日收盘报23.34元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300037924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2582373099","title":"奥锐特：11月11日高管赵珍平减持股份合计5700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373099","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582373099?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:01","pubTimestamp":1762948916,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月12日市场公开信息、上市公司公告及交易所披露数据整理，奥锐特（605116）最新董监高及相关人员股份变动情况：2025年11月11日公司高级管理人员赵珍平共减持公司股份5700.0股，占公司总股本为0.0014%。变动期间公司股价下跌0.13%，11月11日当日收盘报22.85元。奥锐特近半年内的董监高及核心技术人员增减持详情如下：奥锐特的高管列表及最新持股情况如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200036475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2582353864","title":"每周股票复盘：奥锐特（605116）高管减持1.0万股且回购进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2582353864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582353864?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:45","pubTimestamp":1762634712,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，奥锐特报收于22.84元，较上周的23.25元下跌1.76%。股本股东变化高管增减持2025年11月4日，公司高级管理人员赵珍平减持1.0万股，占公司总股本0.0025%。奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告公司于2025年1月21日启动以集中竞价交易方式回购股份，回购期限至2026年1月20日，拟回购金额为6,000万元至12,000万元，用于转换公司可转债。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2581047811","title":"奥锐特（605116）206.6万股限售股将于11月7日解禁，占总股本0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581047811","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581047811?lang=zh_cn&edition=full","pubTime":"2025-11-07 08:05","pubTimestamp":1762473953,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，奥锐特于11月7日将有206.6万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.51%。最近一年内，该股累计解禁868.4万股，占总股本的2.14%。本次解禁后，公司还有1.2万股限售股份，占总股本0.0%。奥锐特主营业务：特色复杂原料药、医药中间体和制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700005652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2580589687","title":"奥锐特（605116）披露股东减持股份计划公告，11月04日股价下跌2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580589687","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580589687?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:27","pubTimestamp":1762266441,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，奥锐特报收于23.45元，较前一交易日下跌2.41%，最新总市值为95.25亿元。近日，奥锐特药业股份有限公司发布股东减持股份计划公告。截至公告日，天台铂恩及其一致行动人合计持有公司股份167,919,800股，占总股本的41.34%。因部分合伙人自身资金需求，天台铂恩拟在2025年11月26日至2026年2月25日期间，通过集中竞价或大宗交易方式减持不超过1,000,000股，即不超过公司总股本的0.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2580780863","title":"奥锐特(605116.SH)：天台铂恩拟减持不超0.25%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780863","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580780863?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:20","pubTimestamp":1762255257,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥锐特(605116.SH)发布公告，因部分合伙人自身资金需求，自公告发布之日起15个交易日后的3个月内(窗口期不减持)，天台铂恩拟通过集中竞价、大宗交易方式减持公司股份不超过100万股，即不超过公司总股本的0.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2580370772","title":"股市必读：奥锐特(605116)股东户数1.15万户，较上期减少2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580370772","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580370772?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:06","pubTimestamp":1762128369,"startTime":"0","endTime":"0","summary":"股东户数变动截至2025年9月30日，奥锐特股东户数为1.15万户，较6月30日减少256户，减幅2.17%；户均持股数量由上期的3.45万股上升至3.53万股，户均持股市值为79.12万元。本次注销后，公司总股本将由406,195,234股减少至406,183,234股，注册资本相应减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251103/31760128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2580706684","title":"每周股票复盘：奥锐特（605116）Q3净利增24.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580706684","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580706684?lang=zh_cn&edition=full","pubTime":"2025-11-02 08:06","pubTimestamp":1762041982,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥锐特报收于23.25元，较上周的22.44元上涨3.61%。本周，奥锐特10月31日盘中最高价报23.32元。股本股东变化截至2025年9月30日，奥锐特股东户数为1.15万户，较6月30日减少256户，减幅2.17%。业绩披露要点奥锐特2025年三季报显示，前三季度主营收入12.37亿元，同比增长13.67%；归母净利润3.54亿元，同比增长24.58%；扣非净利润3.42亿元，同比增长21.46%。本次回购注销后，公司总股本将由406,195,234股减少至406,183,234股，注册资本相应减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2579457703","title":"奥锐特（605116）披露2022年限制性股票激励计划第三个解除限售期解除限售条件成就暨上市流通公告，10月31日股价上涨2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579457703","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579457703?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:23","pubTimestamp":1761906202,"startTime":"0","endTime":"0","summary":"近日，奥锐特药业股份有限公司发布关于2022年限制性股票激励计划第三个解除限售期解除限售条件成就暨上市流通的公告。公司于2025年10月29日召开董事会，审议通过相关议案，确认第三个解除限售期解除限售条件已成就。个人绩效考核均为合格以上，解除限售比例100%。另有1名激励对象离职，其12,000股将被回购注销。本次解除限售后，有限售条件流通股减少至0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251031/31756686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["605116","BK0239"],"gpt_icon":0},{"id":"2579451301","title":"奥锐特(605116)9月30日股东户数1.15万户，较上期减少2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579451301","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579451301?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:31","pubTimestamp":1761903118,"startTime":"0","endTime":"0","summary":"证券之星消息，近日奥锐特披露，截至2025年9月30日公司股东户数为1.15万户，较6月30日减少256.0户，减幅为2.17%。在化学制药行业个股中，奥锐特股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年6月30日至2025年9月30日，奥锐特区间涨幅为7.32%，在此期间股东户数减少256.0户，减幅为2.17%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100036689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0},{"id":"2579783141","title":"图解奥锐特三季报：第三季度单季净利润同比增长24.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579783141","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579783141?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:38","pubTimestamp":1761827911,"startTime":"0","endTime":"0","summary":"证券之星消息，奥锐特2025年三季报显示，前三季度公司主营收入12.37亿元，同比上升13.67%；归母净利润3.54亿元，同比上升24.58%；扣非净利润3.42亿元，同比上升21.46%；其中2025年第三季度，公司单季度主营收入4.15亿元，同比上升16.05%；单季度归母净利润1.19亿元，同比上升24.62%；单季度扣非净利润1.16亿元，同比上升22.5%；负债率37.53%，投资收益520.36万元，财务费用1725.59万元，毛利率60.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605116"],"gpt_icon":0},{"id":"2574706450","title":"每周股票复盘：奥锐特（605116）可转债累计转股313股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574706450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574706450?lang=zh_cn&edition=full","pubTime":"2025-10-12 02:52","pubTimestamp":1760208734,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，奥锐特报收于22.8元，较上周的22.43元上涨1.65%。本周关注点公司公告汇总：截至2025年9月30日，累计已有面值8,000元“奥锐转债”转为公司A股普通股，累计转股股数为313股。公司公告汇总奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告。2025年7月1日至9月30日期间无转股。股本方面，有限售条件流通股由8,684,000股减少至2,078,000股，无限售条件流通股由397,511,234股增至404,117,234股，总股本保持406,195,234股不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605116"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766163222997,"stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":-0.0151},{"period":"3month","weight":-0.019},{"period":"6month","weight":0.0859},{"period":"1year","weight":0.087},{"period":"ytd","weight":0.0685}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"奥锐特药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11515人(较上一季度减少2.17%)","perCapita":"35274股","listingDate":"2020-09-21","address":"浙江省台州市天台县八都工业园区","registeredCapital":"40619万元","survey":" 奥锐特药业股份有限公司的主营业务是特色复杂原料药、医药中间体和制剂的研发、生产和销售。公司的主要产品是呼吸系统、心血管、抗感染、神经系统、抗肿瘤和女性健康类产品。","listedPrice":8.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥锐特,605116,奥锐特股票,奥锐特股票老虎,奥锐特股票老虎国际,奥锐特行情,奥锐特股票行情,奥锐特股价,奥锐特股市,奥锐特股票价格,奥锐特股票交易,奥锐特股票购买,奥锐特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥锐特(605116)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥锐特(605116)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}